Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Convalescent Plasma for Moderate to Severe COVID-19
NCT04412486Phase 1Completed
- Start
- Jun 2020
- Primary completion
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19). Primary endpoints: Change in PaO2/FiO2 at 3 days, Change in pulse oximetry status at 3 days and 3 more. Started Jun 2020; status: completed.
02
Drugs
COVID-19 convalescent plasma
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04412486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04412486.